Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
Pharmabiz20h
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
Telix Pharmaceuticals Limited: Illuccix Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
GlobalData on MSN1d
Telix’s prostate cancer imaging agent approved in Brazil
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Stockhead on MSN2d
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
PR Newswire23d
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Norway
Illuccix, after radiolabelling with gallium-68, is indicated in Norway for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa ...
FNArena1d
The Overnight Report: Weakness Resumes
The S&P500 and Nasdaq Composite remain 1.7% and 1.2% higher, respectively, than Thursday’s close. Mega-cap stocks led today’s ...